The European Medicines Agency (EMA) has introduced new tools under its PRIority MEdicines (PRIME) scheme, reinforcing the EU’s commitment to accelerating the development of innovative therapies addressing unmet medical needs.
PRIME, launched in 2016, is designed to support medicines that demonstrate the potential to offer major therapeutic advantages or benefit patients with limited treatment options. Through early and proactive engagement with developers, the programme aims to optimise development pathways and enable faster patient access without compromising quality, safety, or efficacy.
Under PRIME, developers benefit from:
• Early appointment of a rapporteur and multidisciplinary regulatory support
• Kick-off meetings to align on development strategy
• Continuous scientific advice throughout development
• Guidance on clinical trial design and evidence generation
• Enhanced preparation for marketing authorisation
• Potential eligibility for accelerated assessment
The EMA’s latest announcement makes three pilot features permanent:
• Continuous dialogue between regulators and developers
• Faster, more targeted scientific advice
• Improved preparation for marketing authorisation applications
Together, these enhancements strengthen PRIME’s core objective: reducing development uncertainties and enabling promising medicines, particularly advanced therapies, rare disease treatments, and first-in-class innovations, to reach patients sooner.
PRIME also works alongside other EU early-access tools such as accelerated assessment and conditional marketing authorisation, forming an integrated regulatory framework to support innovation.
As upcoming EU pharmaceutical legislation is expected to further embed these mechanisms, the evolution of PRIME signals a more agile regulatory environment and stronger support for transformative therapies in Europe.
Considering the PRIME programme for your pipeline? Reach out to our team to assess eligibility and optimise your regulatory roadmap at [email protected] or visit our website at www.starodub.nl.
